Julieanne Dorn Professor of Neurology, Massachusetts General Hospital
Neurology
Dr. Merit E. Cudkowicz, MD
|
|
Give Review
Doctor Merit E. Cudkowicz, MD practices Neurology. She went to Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care She received awards:"America's Top Doctors" and "Boston Magazine". Doctor Merit E. Cudkowicz, MD is a published doctor. She has 100 papers published. The most current publication "A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression." Merit E. Cudkowicz accepts Medicare.
Publications
- Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population.
- A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
- Baseline results of the NeuroNEXT spinal Muscular atrophy infant biomarker study.
- Targeting miR-155 restores dysfunctional microglia and ameliorates Disease in the SOD1 model of ALS.
- Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis: C9orf72 Repeats.
- Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
- Disease burden in upper motor neuron syndromes: a survey of patient perspectives.
- Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.
- Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
- Targeting miR-155 restores abnormal microglia and attenuates Disease in SOD1 mice.
- The PRO-ACT database: Design, initial analyses, and predictive features.
- Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS.
- Neuroprotective agents target molecular mechanisms of Disease in ALS.
- A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.
- Seeking a measure of clinically meaningful change in ALS.
- Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).
- Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from Disease mimics.
- Locked in, but not out?
- Systemic pharmacokinetics and cerebroSpinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.
- Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons.
- Predicting success: Optimizing phase II ALS trials for the transition to phase III.
- Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
- Opportunities for improving therapy development in ALS.
- Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial.
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
- Analysis of start-up, retention, and adherence in ALS clinical trials.
- Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS.
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man st...
- 7-T MRI of the spinal cord can detect lateral corticospinal tract Abnormality in amyotrophic lateral sclerosis.
- SOD1 in Cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.
- Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clin...
- The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials.
- Enhancing clinical trials in neurodegenerative Disorders: lessons from amyotrophic lateral sclerosis.
- Developing normalized strength scores for neuroMuscular research.
- Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials.
- Biochemical alterations associated with ALS.
- New considerations in the design of clinical trials for amyotrophic lateral sclerosis.
- Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis.
- Advanced statistical methods to study the effects of gastric tube and non-invasive ventilation on functional decline and survival in amyotrophic lateral sclerosis.
- CSF markers in amyotrophic lateral sclerosis: has the time come?
- Lyme Disease serology in amyotrophic lateral sclerosis.
- The natural history of ALS is changing: Improved survival.
- Profound muscle weakness and Pain after one dose of actonel.
- Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
- Increased incidence of deep venous Thrombosis in ALS.
- Trial of celecoxib in amyotrophic lateral sclerosis.
- Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future.
- Metabolomic analysis and signatures in motor neuron Disease.
- Improving the responsiveness of rating scales: the challenge of stepping twice into the same river.
- Ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis.
- Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells.
- Comparison of incremental with multipoint MUNE methods in transgenic ALS mice.
- IPLEX and the telephone game: the difficulty in separating myth from reality on the internet.
- Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis.
- Clinical trials in progressive neurological Diseases. Recruitment, enrollment, retention and compliance.
- ALS drug development: reflections from the past and a way forward.
- Defining survival as an outcome measure in amyotrophic lateral sclerosis.
- Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients.
- Clinical significance in the change of decline in ALSFRS-R.
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
- Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis.
- Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.
- Safety and tolerability of high-dosage coenzyme Q10 in Huntington''s Disease and healthy subjects.
- Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: Discovery by a proteomics approach.
- A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis.
- Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis.
- Depression in amyotrophic lateral sclerosis.
- Proposed BioRepository platform solution for the ALS research community.
- Emerging targets and treatments in amyotrophic lateral sclerosis.
- Roadmap and standard operating procedures for biobanking and Discovery of neurochemical markers in ALS.
- Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis.
- The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
- Arimoclomol: a potential therapy under development for ALS.
- Toward more efficient clinical trials for amyotrophic lateral sclerosis.
- Emerging Disease-modifying therapies for the treatment of motor neuron Disease/amyotropic lateral sclerosis.
- Design of phase II ALS clinical trials.
- Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials.
- Amyotrophic lateral sclerosis: an emerging era of collaborative gene Discovery.
- Lithium therapy in ALS.
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
- Therapy development for ALS: lessons learned and path forward.
- Thrombopoietin is ineffective in a mouse model of motor neuron Disease.
- Scrutinizing enrollment in ALS clinical trials: room for improvement?
- Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis.
- Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.
- Phase 2 study of sodium phenylbutyrate in ALS.
- Is it too soon for mesenchymal stem cell trials in people with ALS?
- Coenzyme Q treatment of neurodegenerative Diseases of aging.
- Motor unit number estimation predicts Disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis.
- Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis?
- Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS).
- Proteomic profiling of cerebroSpinal fluid identifies biomarkers for amyotrophic lateral sclerosis.
- Measures and markers in amyotrophic lateral sclerosis.
- Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice.
- Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington''s Disease mice.
- Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.
- Biomarkers for amyotrophic lateral sclerosis.
- Translating preclinical insights into effective human trials in ALS.
- Maximum voluntary isometric contraction (MVIC).
Schools
Harvard Medical School
Beth Israel Hospital
Massachusetts General Hospital
Procedures Preformed
- EMG (Electromyography)
- Non-Cosmetic Chemodenervation
Conditions Treated
- Anterior Horn Disease
- Ataxia
- Autonomic Disorders
- Cerebral Artery Thrombosis
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
Education
-
Massachusetts General Hospital -
Beth Israel Deaconess Medical Center -
Harvard Medical School
Hospital
-
Beth Israel Deaconess Medical Center -
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1306827241 | |
| NPPES Provider LastName | CUDKOWICZ | |
| NPPES Provider FirstName | MERIT | |
| NPPES Provider ZIPCode | 021143117 | |
| NPPES Provider State | MA | |
| Specialty Description | Neurology | |
| Total Claim Count | 156.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306827241 |
| Last Name Of The Provider | CUDKOWICZ |
| First Name Of The Provider | MERIT |
| View All |
Similar Doctors
|
|
Dr. Heather E. Olson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xuemei Cai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendon P. Boot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronan J. Walsh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claire S. Jacobs, MD |
|
|
Dr. Joo Y. Nam, MD |
|
|
Dr. Sarah Dodwell, MD |
|
|
Dr. Bonnie P. Hersh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammad Salajegheh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David L. Perez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathy Chuang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen W. Parker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diler Acar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimiko Domoto-Reilly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alcy R. Torres, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ari J. Wilkenfeld, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bart Thaci, MD |